Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A major cardiovascular drug trial failure is fueling debate over whether all adults should be screened for lipoprotein(a). Earlier this year, 11 cardiology societies recommended universal Lp(a) blood testing, but the HORIZON trial — testing a drug designed to lower Lp(a) — failed to reduce heart events. Now, prominent physicians are questioning whether the screening recommendation does more harm than good.
A high-profile clinical trial failure is reigniting a heated debate in cardiology. In March, a coalition of 11 cardiology societies issued landmark guidelines recommending that all adults be tested for lipoprotein(a) — a genetically inherited heart disease risk marker — at least once in their lifetime. The move followed similar recommendations from European cardiology bodies. But the HORIZON trial, which tested pelacarsen (an antisense oligonucleotide drug designed to lower Lp(a) levels), reduced Lp(a) but failed to reduce major cardiovascular events, leaving clinicians questioning what to do with high scores.
Critics argue the test creates unnecessary anxiety, triggers costly downstream testing, and offers little actionable guidance since Lp(a) can't be modified by diet, exercise, or most medications. Supporters, including the guidelines committee chair, counter that Lp(a) is a strong causal risk factor for atherosclerosis and aortic valve disease, and that knowing one's score can motivate lifestyle improvements.
Key Takeaways:
Why it matters: With no proven Lp(a)-targeted therapy now available, HCPs face a real dilemma — screen widely and risk patient anxiety without clear next steps, or hold off and potentially miss a meaningful risk signal in younger, otherwise healthy patients.